Growth Funding Growth equity investment from 1315 Capital signals validated market potential and funding readiness for scale. Use this momentum to discuss expanded manufacturing, capacity expansion, and broader distribution partnerships in consumer health and prescription products.

Product Portfolio Diverse product lines including Nitro-Dur and Cushion Grip with pharma-equivalent offerings across consumer health and prescription segments create cross-selling opportunities for turnkey manufacturing, regulatory support, and co-branding with distributors and retailers.

Manufacturing Capabilities State-of-the-art facility and strong development/manufacturing expertise present a compelling case for contract manufacturing, tech transfer, and accelerated product launches for partners seeking reliable supply and quality compliance.

Global Reach Multi-national footprint and partner network indicate readiness to expand international distribution, licensing, and market access collaborations, especially for generic and branded equivalents in new regions.

Financial Scale Revenue in the mid tens of millions with a lean employee base suggests agility for fast-tracked deals, favorable economics for manufacturing agreements, and strategic investments in high-demand consumer and prescription products.